全球骨髓增生性疾病药物/治疗市场研究报告 - 产业分析、规模、份额、成长、趋势及预测（2025 年至 2033 年）

全球骨髓增生性疾病药物/治疗市场预计将经历显着扩张，预计 2025 年至 2033 年的年复合成长率(CAGR) 为 3.48%。根据市场分析，预计到 2033 年底市场规模将达到 138.2 亿美元，高于 2024 年的 101.6 亿美元。

全球骨髓增生性疾病 (MPD) 药物及治疗市场预计将在诊断率不断提高和标靶治疗技术进步的推动下实现成长。 JAK 抑制剂和干扰素製剂等新型药物正在改善疾病管理和患者预后。未来的发展将侧重于联合疗法、个人化医疗方法以及用于早期检测和治疗监测的新型生物标记。

此外，临床试验和监管审批的不断增加正在加速创新疗法的市场化。患者权益倡导和认知项目的兴起正在提高诊断率和依从性。基因组分析和数位健康工具的进步正在促进精准医疗的发展。随着血液肿瘤学的发展，MPD药物和治疗市场将继续创新，提供有效、客製化且更安全的治疗方案。

目录

第一章：前言

• 报告描述
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法
  • 市场研究流程
  • 市场研究方法

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：骨髓增生性疾病药物/治疗 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业趋势
• 波特五力分析
• 市场吸引力分析
  • 依疾病类型分析市场吸引力
  • 按药品类别分析市场吸引力
  • 按给药途径进行的市场吸引力分析
  • 按最终用途进行的市场吸引力分析
  • 市场吸引力分析：按地区

第四章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料製造商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第五章：全球骨髓增生性疾病药物/治疗市场分析：依疾病类型

• 依疾病类型概述
• 依疾病类型分析历史和预测数据
• 费城染色体阳性（Ph+）慢性骨髓性白血病
• 费城染色体阴性（Ph-）MPN
• 真性红血球增多症
• 原发性血小板增多症
• 骨髓纤维化
• 其他疾病类型

第六章：全球骨髓增生性疾病药物/治疗市场分析：依药物类别

• 按药物类别概述
• 按药物类别进行的历史和预测数据分析
• 酪胺酸激酶抑制剂
• Janus激酶抑制剂
• 羟基脲
• 其他药物类别

第七章：全球骨髓增生性疾病药物/治疗市场分析：依给药途径

• 依给药途径概述
• 按给药途径进行的历史和预测数据分析
• 口服
• 注射剂

第 8 章：全球骨髓增生性疾病药物/治疗市场分析：依最终用途

• 按最终用途概述
• 按最终用途进行的历史和预测数据分析
• 医院
• 专科诊所
• 其他最终用户

第九章：全球骨髓增生性疾病药物/治疗市场分析：按地区

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美各细分市场销售分析
  • 北美各国销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲各细分市场销售分析
  • 欧洲各国销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区分部销售分析
  • 亚太地区国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲各细分市场销售分析
  • 拉丁美洲各国销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲分部销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东和非洲其他地区销售分析

第 10 章：骨髓增生性疾病药物/治疗公司的竞争格局

• 骨髓增生性疾病药物/治疗市场竞争
• 伙伴关係/合作/协议
• 併购
• 新产品发布
• 其他发展

第 11 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• AbbVie Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Bristol-Myers Squibb Company
• 公司概况
• 公司收入
• 产品
• 最新动态
• Eli Lilly And Company
• 公司概况
• 公司收入
• 产品
• 最新动态
• GlaxoSmithKline Plc (GSK)
• 公司概况
• 公司收入
• 产品
• 最新动态
• GL Pharma GmbH Incyte Corporation
• 公司概况
• 公司收入
• 产品
• 最新动态
• Janssen Biotech Inc. (Johnson & Johnson)
• 公司概况
• 公司收入
• 产品
• 最新动态
• MorphoSys AG
• 公司概况
• 公司收入
• 产品
• 最新动态
• Mylan NV (Viatris)
• 公司概况
• 公司收入
• 产品
• 最新动态
• Novartis Pharmaceuticals Corporation (Novartis AG)
• 公司概况
• 公司收入
• 产品
• 最新动态
• Takeda Pharmaceutical Company Limited
• 公司概况
• 公司收入
• 产品
• 最新动态
• Teva Pharmaceutical Industries Ltd
• 公司概况
• 公司收入
• 产品
• 最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，或者在私人公司的情况下可能不涵盖

Global Myeloproliferative Disorders Drugs/Treatment Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 3.48% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 13.82 Billion by the end of 2033, up from USD 10.16 Billion in 2024.

The global myeloproliferative disorders (MPD) drugs and treatment market is set for growth driven by increasing diagnosis rates and advancements in targeted therapies. Novel agents such as JAK inhibitors and interferon formulations are improving disease management and patient outcomes. Future developments will focus on combination therapies, personalized medicine approaches, and novel biomarkers for early detection and treatment monitoring.

Additionally, expanding clinical trials and regulatory approvals are accelerating market availability of innovative treatments. The rise of patient advocacy and awareness programs is enhancing diagnosis and adherence. Advances in genomic profiling and digital health tools are facilitating precision medicine. As hematologic oncology evolves, the MPD drugs and treatment market will continue to innovate, delivering effective, tailored, and safer therapeutic options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Myeloproliferative Disorders Drugs/Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disorder Type

• Philadelphia Chromosome-Positive (Ph+) CML
• Philadelphia Chromosome-Negative (Ph-) MPNs
• Polycythemia Vera
• Essential Thrombocythemia
• Myelofibrosis
• Other Disorder Types

By Drug Class

• Tyrosine Kinase Inhibitors
• Janus Kinase Inhibitors
• Hydroxyurea
• Other Drug Classes

By Route Of Administration

• Oral
• Injectable

By End-Use

• Hospitals
• Specialty Clinics
• Other End-Users
• List of Companies Profiled in the report
• AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma GmbH Incyte Corporation, Janssen Biotech Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disorder Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Route Of Administration
  • 3.7.4 Market Attractiveness Analysis By End-Use
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DISORDER TYPE

• 5.1. Overview By Disorder Type
• 5.2. Historical and Forecast Data Analysis By Disorder Type
• 5.3. Philadelphia Chromosome-Positive (Ph+) CML Historic and Forecast Sales By Regions
• 5.4. Philadelphia Chromosome-Negative (Ph-) MPNs Historic and Forecast Sales By Regions
• 5.5. Polycythemia Vera Historic and Forecast Sales By Regions
• 5.6. Essential Thrombocythemia Historic and Forecast Sales By Regions
• 5.7. Myelofibrosis Historic and Forecast Sales By Regions
• 5.8. Other Disorder Types Historic and Forecast Sales By Regions

6. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Tyrosine Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.4. Janus Kinase Inhibitors Historic and Forecast Sales By Regions
• 6.5. Hydroxyurea Historic and Forecast Sales By Regions
• 6.6. Other Drug Classes Historic and Forecast Sales By Regions

7. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 7.1. Overview By Route Of Administration
• 7.2. Historical and Forecast Data Analysis By Route Of Administration
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Injectable Historic and Forecast Sales By Regions

8. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY END-USE

• 8.1. Overview By End-Use
• 8.2. Historical and Forecast Data Analysis By End-Use
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Specialty Clinics Historic and Forecast Sales By Regions
• 8.5. Other End-Users Historic and Forecast Sales By Regions

9. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT COMPANIES

• 10.1. Myeloproliferative Disorders Drugs/Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Bristol-Myers Squibb Company
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Eli Lilly And Company
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. GlaxoSmithKline Plc (GSK)
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. GL Pharma GmbH Incyte Corporation
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Janssen Biotech Inc. (Johnson & Johnson)
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. MorphoSys AG
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Mylan N.V. (Viatris)
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Novartis Pharmaceuticals Corporation (Novartis AG)
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Takeda Pharmaceutical Company Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Teva Pharmaceutical Industries Ltd
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Disorder Type (USD MN)
• Philadelphia Chromosome-Positive (Ph+) CML Market Sales By Geography (USD MN)
• Philadelphia Chromosome-Negative (Ph-) MPNs Market Sales By Geography (USD MN)
• Polycythemia Vera Market Sales By Geography (USD MN)
• Essential Thrombocythemia Market Sales By Geography (USD MN)
• Myelofibrosis Market Sales By Geography (USD MN)
• Other Disorder Types Market Sales By Geography (USD MN)
• Analysis By Drug Class (USD MN)
• Tyrosine Kinase Inhibitors Market Sales By Geography (USD MN)
• Janus Kinase Inhibitors Market Sales By Geography (USD MN)
• Hydroxyurea Market Sales By Geography (USD MN)
• Other Drug Classes Market Sales By Geography (USD MN)
• Analysis By Route Of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Analysis By End-Use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Specialty Clinics Market Sales By Geography (USD MN)
• Other End-Users Market Sales By Geography (USD MN)
• Global Myeloproliferative Disorders Drugs/Treatment Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Myeloproliferative Disorders Drugs/Treatment Report
• Market Research Process
• Market Research Methodology
• Global Myeloproliferative Disorders Drugs/Treatment Market Size, By Regions (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Disorder Type
• Market Attractiveness Analysis By Drug Class
• Market Attractiveness Analysis By Route Of Administration
• Market Attractiveness Analysis By End-Use
• Market Attractiveness Analysis By Regions
• Value Chain Analysis
• Global Market Analysis By Disorder Type (USD MN)
• Philadelphia Chromosome-Positive (Ph+) CML Market Sales By Geography (USD MN)
• Philadelphia Chromosome-Negative (Ph-) MPNs Market Sales By Geography (USD MN)
• Polycythemia Vera Market Sales By Geography (USD MN)
• Essential Thrombocythemia Market Sales By Geography (USD MN)
• Myelofibrosis Market Sales By Geography (USD MN)
• Other Disorder Types Market Sales By Geography (USD MN)
• Global Market Analysis By Drug Class (USD MN)
• Tyrosine Kinase Inhibitors Market Sales By Geography (USD MN)
• Janus Kinase Inhibitors Market Sales By Geography (USD MN)
• Hydroxyurea Market Sales By Geography (USD MN)
• Other Drug Classes Market Sales By Geography (USD MN)
• Global Market Analysis By Route Of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Injectable Market Sales By Geography (USD MN)
• Global Market Analysis By End-Use (USD MN)
• Hospitals Market Sales By Geography (USD MN)
• Specialty Clinics Market Sales By Geography (USD MN)
• Other End-Users Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.